Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Summary of Disaggregated Amounts that Comprise Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses:


		Three Months Ended March 31,
		2026				2025
External research and development expenses:
Clinical trials expenses		$	755			$	528
Consulting and outside services			748				632
Other external research and development (1)			2,442				3,960
Total external research and development expenses			3,945				5,120

Internal research and development expenses:
Personnel related expenses			2,798				2,570
Total research and development expenses		$	6,743			$	7,690

(1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.